Abstract: Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: This invention provides substituted indole and indoline compounds useful in inhibiting phospholipase activity, particularly including cytosolic phospholipase A2 (cPLA2) activity, as well as pharmaceutical compositions containing the compounds and methods of using them to treat various maladies, including pain and inflammatory conditions.

Abstract: Provided by the present invention are novel methods of factor IX protein recovery and purification.

Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed.

Abstract: Purified BMP-16 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-16 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, lung, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells.

Abstract: Methods and compositions are provided for the treatment of periodontal disease and bone lesions. Preferred methods comprise administering a composition containing one or more osteogenic and/or ligament-inducing bone morphogenetic protein and a suitable carrier. The method results in the regeneration of alveolar bone in both a vertical and horizontal direction, and can result in the regeneration of bone, cementum and ligamentous structure between said regenerated bone and the tooth root surface, such that minimal ankylosis and root resorption results. The method and composition are useful for the repair of supraalveolar periodontal lesions and defects, mandibular and maxillary class II and III furcations and interproximal defects, and augmentation of the alveolar ridge of these structures.

Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.

Abstract: Novel serine/threonine receptor proteins and BMP receptor proteins are disclosed, as well as DNA molecules encoding these proteins and methods of using the receptor proteins. Further disclosed are truncated BMP receptor proteins and molecules which act as ligands to these BMP receptor proteins.

Abstract: Purified BMP-17 and BMP-18 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-17 and BMP-18 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, lung, epithelium, brain, spleen, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells.

Abstract: Methods are disclosed for refolding proteins of the TGF-&bgr; family of proteins. The methods employ as refolding agents one or more compounds which are non-detergent zwitterionic compounds, such as sulfobetaines, substituted pyridines, substituted pyrroles and acid substituted aminocyclohexanes.

Abstract: Methods are disclosed for refolding proteins of the TGF-&bgr; family of proteins. The methods employ as refolding agents one or more compounds which are substituted pyridines.

Abstract: Methods are disclosed for refolding proteins of the TGF-&bgr; family of proteins. The methods employ as refolding agents one or more compounds which are non-detergent zwitterionic compounds, such as sulfobetaines, substituted pyridines, substituted pyrroles and acid substituted aminocyclohexanes.

Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

Abstract: This invention concerns compounds and pharmaceutical compositions useful for treating or preventing inflammatory conditions in a mammal, the methods comprising administration of novel pharmaceutically useful compounds of the general formulae: or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined in the specification.

Abstract: Purified BMP-17 and BMP-18 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-17 and BMP-18 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, lung, epithelium, brain, spleen, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells.

Abstract: Crystallographic and NMR solution structures of human IL-6 are reported. The invention provides models and systems incorporating such structures which are useful for identifying IL-6/IL-6 receptor interactions and for identification of agonists and antagonists of such interactions. Crystalline human IL-6 is also provided.

Abstract: Novel proteins are disclosed.

Abstract: Novel human megakaryocyte stimulating factors (MSFS) capable of stimulating the growth and development of colonies of megakaryocytes, pharmaceutical compositions containing same, and methods for their preparation and use are provided.